Skip to content

Medical Devices; General and Plastic Surgery Devices; Classification of the Software-Aided Adjunctive Diagnostic Device for Use by Physicians on Lesions Suspicious for Skin Cancer

Final rule · Federal Register document 2026-22179

Published
10/30/2026
Effective
10/30/2026
Pages
3

Summary

Final amendment; final order.

The Food and Drug Administration (FDA) is classifying the software-aided adjunctive diagnostic device for use by physicians on lesions suspicious for skin cancer into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the software-aided adjunctive diagnostic device for use by physicians on lesions suspicious for skin cancer. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

Read the official textPDF on GovInfo

Details

Type
Final rule
Docket
Docket No. FDA-2026-N-12213
CFR parts
21 CFR 878
Topics
Medical devices

This page summarizes a Federal Register document. Only the official Federal Register text has legal effect. Comment deadlines can be extended or reopened by a later notice.

Source: Office of the Federal Register, via the Federal Register API · Last updated 10/30/2026

Share: